For the quarter ending 2025-09-30, BBLG had -$591,384 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Research and development | 187,808 | - |
| Salaries | 125,000 | - |
| Insurance | 71,777 | - |
| Stock-based compensation | 87,180 | - |
| Operating expenses | 242,297 | - |
| Interest income | 74,020 | - |
| Net loss | -666,737 | -1,757,611 |
| Stock-based compensation | 87,180 | 123,504 |
| Change in fair value of warrant liability | -1,212 | -2,257 |
| Research and development contract liabilities | - | 0 |
| Advances on research and development contract services | -11,314 | 49,087 |
| Prepaid insurance and prepaid expenses | -71,347 | -125,403 |
| Accrued legal settlement | - | 0 |
| Accounts payable and accrued expenses | -70,648 | 76,870 |
| Net cash used in operating activities | -591,384 | -1,385,004 |
| Exercise of pre-funded warrants | - | 0 |
| Proceeds from issuance of common shares from atm, net of costs | 0 | 347,549 |
| Proceeds from sale of common stock, warrants, and pre-funded warrants in public offering, net of offering costs | 0 | 4,352,792 |
| Net cash provided by financing activities | 0 | 4,700,341 |
| Net increase in cash | -591,384 | 3,315,337 |
| Cash and cash equivalents at beginning of period | 3,325,131 | - |
| Cash and cash equivalents at end of period | 6,049,084 | - |
Bone Biologics Corp (BBLG)
Bone Biologics Corp (BBLG)